CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction
Key facts
- Where
- Copenhagen, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07493590, who can take part
Where in Denmark
- Herlev and Gentofte HospitalCopenhagen, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Herlev and Gentofte Hospital
- Trial code
- NCT07493590
- Record updated
- 25 March 2026
- Original description
The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and women across Danish regions.Read full original descriptionShow less
CAPTURE-HFpEF (Cardiovascular Assessment and Phenotyping for Timely Understanding and Recognition of Evolving Heart Failure With Preserved Ejection Fraction)
The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and women across Danish regions.
The main questions to answer are:
Can systematic cardiovascular screening and deep phenotyping improve early identification and classification of HFpEF?
Which clinical, imaging, biomarker, and metabolic characteristics define subtypes (phenotypes) of HFpEF and predict disease progression and outcomes?
Researchers will compare participants with HFpEF, participants at risk of HFpEF, and relevant control groups to see if differences in biomarkers, imaging findings, and clinical characteristics can identify early disease stages and distinct HFpEF phenotypes.
Participants identified with HFpEF will:
* Undergo detailed cardiovascular examinations (e.g., echocardiography, CT and other imaging examinations, RHC, CPET) * Provide blood and tissue samples for biomarker and metabolic analyses * Complete clinical assessments and questionnaires * Have relevant health data collected from national health registries * Attend follow-up assessments to monitor disease progression
Inclusion: Patients >60 years with ≥1 risk factor, OR; Patients >50 years with ≥2 risk factors; Hypertension; Type 1 or 2 diabetes; Chronic kidney disease (eGFR <60 mL/min/1.73 m²); Previous cardiotoxic drug exposure; atrial fibrillation; Ischemic heart disease; Previous heart valve surgery/intervention; Body mass index >30 kg/m² (self-reported); Use of ≥40 mg furosemide; Obstructive sleep apnea; Non-alcoholic fatty liver disease.
Exclusion: Prior organ-transplantation; Cancer <1 year; Dementia; Age >90 years; Dialysis; COPD and O2; Nursing home; Known dilated cardiomyopathy; Amyloidosis.